Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.62 |
| ▸ | MEN1 | O00255 | 6/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6926773 | 0.89 | ALDH1A1 (0.62) | KMT2AMEN1POLBALDH1A1MAPT | |
| SCHEMBL6931428 | 0.87 | ALDH1A1 (0.59) | KMT2AMEN1POLBALDH1A1MAPT | |
| SCHEMBL6931395 | 0.86 | TP53 (0.52) | KMT2AMEN1POLBALDH1A1MAPT | |
| SCHEMBL6931746 | 0.86 | KMT2A (0.52) | KMT2AMEN1POLBALDH1A1MAPT | |
| SCHEMBL6930455 | 0.86 | FAAH (0.56) | KMT2AMEN1POLBALDH1A1MAPT | |
| SCHEMBL6926103 | 0.83 | TRPV1 (0.50) | POLBALDH1A1RAB9ANPC1FAAH | |
| SCHEMBL6930410 | 0.83 | KMT2A (0.74) | KMT2AMEN1POLBATMALDH1A1 | |
| SCHEMBL10192033 | 0.82 | ALDH1A1 (0.61) | KMT2AMEN1POLBALDH1A1MAPT | |
| SCHEMBL6926264 | 0.81 | KMT2A (0.72) | KMT2AMEN1POLBATMALDH1A1 | |
| SCHEMBL11162042 | 0.80 | RAB9A (0.56) | KMT2AMEN1ATMALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624196-B2 | Particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, cardiovascular disorders | WARNER-LAMBERT COMPANY | 2003-09-23 | — | — | US | claimed |
| US-6541521-B1 | Particularly gelatinase A, collagenase-3, and stromelysin-1 | WARNER-LAMBERT COMPANY | 2003-04-01 | — | — | US | claimed |
| US-20020161050-A1 | Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY (US) | 2002-10-31 | — | — | US | claimed |
| US-6624196-B2 | Particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, cardiovascular disorders | WARNER-LAMBERT COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-6541521-B1 | Particularly gelatinase A, collagenase-3, and stromelysin-1 | WARNER-LAMBERT COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-20020161050-A1 | Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY (US) | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161050-A1 | Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases | MMP1, MMP8, MMP13 | KMT2A 4700/4885MEN1 3055/4885POLB 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.